<DOC>
	<DOCNO>NCT00648817</DOCNO>
	<brief_summary>Metabolic change commonly occur HIV therapy . The purpose study assess impact insulin sensitivity administration tenofovir disoproxil fumarate 300 mg compare placebo non-HIV-1 infect healthy adult male . Additionally , endothelial function , adipocytokines lipid monitor .</brief_summary>
	<brief_title>Metabolic Impact Assessment Tenofovir Disoproxil Fumarate Non-HIV-1 Infected Healthy Adult Male Volunteers</brief_title>
	<detailed_description>Double-blind , randomize , placebo-controlled study use two-sequence two-period crossover structure . Sixteen HIV-1-negative male randomize 1:1 one two treatment arm . Group 1 : - Tenofovir DF 300 mg QD ( equivalent 245 mg tenofovir disoproxil ) first 14 day study . - Tenofovir DF placebo tablet QD last 14 day study . Group 2 : - Tenofovir DF placebo tablet QD first 14 day study . - Tenofovir DF 300 mg QD ( equivalent 245 mg tenofovir disoproxil ) last 14 day study . Physical examination laboratory analysis conduct screening , baseline , Day 14 , Day 28 . A euglycaemic clamp protocol ECG perform baseline , Day 14 Day 28 visit . The primary efficacy endpoint study insulin-mediated glucose disposal hyperinsulinaemic euglycaemic clamp study . Endothelial function monitor Selectin P/E PAI-1 level ; adipocytokine level monitor measure adiponectin leptin level ; lipid subfractions , include cholesterol ( large small subfractions HDL LDL ) triglycerides non-esterified fatty acid measure . Safety evaluate adverse event clinical laboratory test reporting .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Subjects must document negative HIV serology ELISA P24 antigen . This do screening visit . Subjects must clinically well male age 18 55 year . Adequate renal function : Calculated creatinine clearance ( CrCl ) &gt; = 100 mL/min accord Cockcroft Gault formula : Male : [ ( 140 age year ) x ( actual body wt kg ) ] / [ 72 x ( serum creatinine mg/dL ) ] = CrCl ( mL/min ) Fasting blood glucose , total cholesterol triglyceride within normal limit Hepatic transaminase ( AST ALT ) &lt; = 3 x upper limit normal ( ULN ) Total bilirubin &lt; = 1.5 mg/dL Adequate hematologic function ( absolute neutrophil count &gt; = 1,000/mm3 ; platelet &gt; = 50,000/mm3 ; hemoglobin &gt; = 8.0 g/dL ) Serum amylase &lt; = 1.5 x ULN ( subject serum amylase &gt; 1.5 x ULN remain eligible pancreatic lipase &lt; = 1.5 x ULN ) Serum phosphorus &gt; = 2.2 mg/dL Sexually active male must use condoms Life expectancy &gt; = 1 year The ability understand sign write informed consent form , must obtain prior initiation study procedure Subjects waist hip ratio &gt; 0.97 BMI &gt; 28 kg/m2 exclude Acute chronic hepatitis B infection ( determine positive hepatitis B surface antigen result screen visit ) Acute chronic hepatitis C infection ( determine positive hepatitis C antibody result screen visit ) Other metabolic syndrome disease process likely cause mark disturbance glucose lipid homeostasis Receiving ongoing therapy following : Metabolically active medication Any lipidlowering medication Hormonal agent ( oestrogen androgen ) Glucocorticoids Betablockers Thiazide diuretic Thyroid preparation Psychotropic agent Anabolic steroid Megoestrol acetate Nephrotoxic agent aminoglycoside antibiotic IV amphotericin B cidofovir cisplatin foscarnet IV pentamidine agent significant nephrotoxic potential Vancomycin Oral IV ganciclovir Agents inhibit compete elimination via active renal tubular secretion ** Probenecid Systemic chemotherapeutic agent ( i.e. , cancer treatment medication ) Systemic corticosteroid Interleukin 2 ( IL 2 ) immunomodulating agent Investigational agent Administration medication must discontinue least 30 day prior baseline visit duration study period . Evidence gastrointestinal malabsorption syndrome chronic nausea vomiting may confer inability receive orally administer medication . Current alcohol substance abuse judge investigator potentially interfere subject compliance . Malignancy basal cell carcinoma . Active , serious infection require parenteral antibiotic therapy within 15 day prior screen . Prior history significant renal bone disease . Subjects avoid give blood duration study . Any clinical condition prior therapy , opinion investigator , would make subject unsuitable study unable comply dose requirement .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>tenofovir DF</keyword>
</DOC>